ArticleNutrition journal2025
Free thyroxine modifying the association of serum ferritin with gestational diabetes risk: A retrospective cohort study.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBoth serum ferritin (SF) and thyroxine (fT4) are associated with the risk of gestational diabetes mellitus (GDM). However, whether and how they interact to modulate GDM risk has yet to be fully explored.
objectiveThis study aimed to determine the effect modification of fT4 on the association of SF and GDM, and to further identify the SF safety range while considering fT4 levels.
methodsA retrospective cohort study was conducted in 15,627 pregnant women enrolled from the Southwest region of China between 2018 and 2022. A modified Poisson regression and restricted cubic splines were used to assess the linear and non-linear associations of SF and fT4 with GDM risk in a trimester-specific manner, respectively. Stratified and interaction analyses were performed to evaluate the modification effect of fT4 on SF-GDM relationship. Various sensitivity analyses were conducted.
resultsBoth fT4 and SF were linearly associated with GDM risk during early and mid-pregnancy (all Passociation<0.05). Furthermore, fT4 significantly interacted with SF to modulate GDM risk in the first trimester (Pinteraction = 0.012). During early pregnancy, SF was positively associated with GDM risk only at low fT4 levels, with an identified upper risk cut-off for SF of 150 ng/mL (Ptrend=0.005). Whereas in mid-pregnancy, high SF (> 15 ng/mL) and low fT4 were independent risk factors for GDM (Passociation<0.05).
conclusionsThis study provides the first evidence that SF interacts with fT4 to modulate GDM risk in a trimester-dependent manner, highlighting the importance of monitoring ferritin levels in the context of thyroid function across different gestational stages for effective GDM prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.